← Back to Screener
Whitehawk Therapeutics, Inc. Common Stock (WHWK)
Price$4.23
Favorite Metrics
Price vs S&P 500 (26W)100.46%
Price vs S&P 500 (4W)7.75%
Market Capitalization$193.98M
All Metrics
Book Value / Share (Quarterly)$2.89
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-22.28%
Cash Flow / Share (Quarterly)$-2.08
Price vs S&P 500 (YTD)70.86%
Gross Margin (TTM)88.72%
Net Profit Margin (TTM)99.42%
EPS (TTM)$-1.44
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-1.44
Revenue Growth (5Y)-13.79%
EPS (Annual)$-0.44
ROI (Annual)-15.11%
Gross Margin (Annual)89.36%
Net Profit Margin (5Y Avg)-2206.09%
Cash / Share (Quarterly)$3.09
ROA (Last FY)-13.66%
Revenue Growth TTM (YoY)-72.50%
EBITD / Share (TTM)$-0.57
ROE (5Y Avg)-63.58%
Operating Margin (TTM)87.41%
Cash Flow / Share (Annual)$-2.08
P/B Ratio1.42x
P/B Ratio (Quarterly)0.84x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-193.55x
ROA (TTM)-11.24%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)10.26x
Quick Ratio (Quarterly)10.03x
3-Month Avg Trading Volume0.17M
52-Week Price Return169.43%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)27.15x
Asset Turnover (Annual)0.05x
52-Week High$4.48
Operating Margin (5Y Avg)-2251.81%
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)94.17%
26-Week Price Return107.35%
Quick Ratio (Annual)10.03x
13-Week Price Return51.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.26x
Enterprise Value$156.41
Revenue / Share Growth (5Y)-50.84%
Asset Turnover (TTM)0.23x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.29x
Pretax Margin (Annual)-288.26%
Cash / Share (Annual)$3.09
3-Month Return Std Dev70.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-15.11%
Net Interest Coverage (Annual)-330.67x
EPS Basic Excl Extra (Annual)$-0.44
Receivables Turnover (TTM)2.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.44
Receivables Turnover (Annual)2.42x
ROI (TTM)-11.99%
P/S Ratio (TTM)6.98x
Pretax Margin (5Y Avg)-2206.09%
Revenue / Share (Annual)$0.15
Price vs S&P 500 (52W)134.79%
Year-to-Date Return74.79%
5-Day Price Return5.75%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-51.29%
Net Profit Margin (Annual)-288.26%
Month-to-Date Return22.61%
EBITD / Share (Annual)$-0.57
Operating Margin (Annual)-379.76%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-62.90%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.44
P/B Ratio (Annual)0.84x
Inventory Turnover (TTM)0.29x
Pretax Margin (TTM)99.42%
Book Value / Share (Annual)$2.89
Price vs S&P 500 (13W)49.23%
Beta0.78x
Revenue / Share (TTM)$0.69
ROE (TTM)-11.99%
52-Week Low$1.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.80
3.80
3.91
3.91
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
WHWKWhitehawk Therapeutics, Inc. Common Stock | 6.98x | -72.50% | 88.72% | — | $4.23 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Whitehawk Therapeutics is a preclinical-stage oncology company developing next-generation antibody-drug conjugates for difficult-to-treat cancers. Its three-asset ADC portfolio is engineered to overcome first-generation limitations and improve therapeutic efficacy.